TABLE 2.

Clinical data for patients with candidemia who failed to respond to therapy with fluconazole

Patient/mode of failure	Age	Critically ill	Cancerb	Transplanta	Neutropenia	Candida sp.	24-h MIC (μg/ml)	48-h MIC (μg/ml)	Daily fluconazole dosage (mg)	24-h dose/ MIC ratio	48-h dose/ MIC ratio
Failurec
4	62	Yes	AML	No	Yes	C. glabrata	4	16	200	50	12.5
2	64	Yes	Renal cell carcinoma	No	Yes	C. tropicalis	1	2	200	200	100
14	42	No	None	No	No	C. parapsilosis	0.5	1	200	400	200
7	51	Yes	Unknown solid cancer	Heart	No	C. albicans	0.5	0.5	200	400	400
Breakthroughd
6	48	No	Lymphoma	No	Yes	C. parapsilosis	0.5	1	200	400	200
8	14	No	ALL	BMT	No	C. albicans	1	1	100	100	100
15	2	No	AML	No	Yes	C. glabrata	2	8	200	100	25
12	43	No	AML	BMT	Yes	C. parapsilosis	1	32	100	100	3.125
9	2	No	None	No	Yes	C. albicans	1	1	50	50	50
5	48	Yes	ALL	BMT	No	C. glabrata	16	16	200	12.5	12.5
10	51	No	ALL	No	Yes	C. krusei	32	64	400	12.5	6.25
17	71	Yes	Myelofibrosis/ polycythemia vera	No	No	C. lusitaniae	32	32	200	6.25	6.25
16	48	No	Leukemia	BMT	Yes	C. krusei	64	64	200	3.125	3.125
1	63	Yes	Multiple Myeloma	No	Yes	C. krusei	64	>64	200	3.125	1.56
11	48	No	ALL	BMT	Yes	C. krusei	32	64	100	3.125	1.56
13	42	No	Lymphoma	No	Yes	C. albicans	64	>64	200	3.125	1.56
3	32	Yes	Aplastic anemia	BMT	Yes	C. glabrata	64	>64	100	1.56	0.78

^aBMT, bone marrow transplant.

^bAML, acute myelogenous leukemia; ALL, acute lymphocytic leukemia.

^cFailure, patients with persistent candidemia despite 3 days of fluconazole therapy.

^dBreakthrough, patients who developed candidemia while receiving at least 3 days of fluconazole for empiric therapy.